secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enveric Biosciences, Inc. (ENVB)
CIK:        0000890821
Form:       8-K
Filed at:   2023-05-24T23:59:59+00:00
Accession:  0001493152-23-018784
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 1.02, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Enveric Biosciences cuts 35% of workforce, eliminates President/COO role
------------------------------------------------------------------------

- Announced ~35% reduction in force on May 15, 2023.
- Eliminated President and COO positions; Avani Kanubaddi terminated effective June 17, 2023.
- Severance includes 12 months base salary continuation and acceleration of unvested RSUs.
- Performance bonus for 2023 may be paid if metrics achieved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/890821/000149315223018784/0001493152-23-018784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/890821/000149315223018784/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-018784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer